RECRUITING

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.

Official Title

A Prospective, Observational, Long-term Follow-up Study for Subjects Who Previously Received Zamtocabtagene Autoleucel in a United States Miltenyi Biomedicine-Sponsored Clinical Study

Quick Facts

Study Start:2024-05-15
Study Completion:2039-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06116110

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Received zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study and have either completed the study or have discontinued early from the study.
  2. * Provided written informed consent to participate in this study.
  1. * None

Contacts and Locations

Study Contact

Sadie Swift
CONTACT
617-218-0044
clinicaltrials@miltenyi.com
Paris Jamiel
CONTACT
617-218-0044
clinicaltrials@miltenyi.com

Principal Investigator

Remi Kaleta, MD
STUDY_DIRECTOR
Miltenyi Biomedicine GmbH

Study Locations (Sites)

Stanford University
Stanford, California, 94305
United States
Yale University
New Haven, Connecticut, 06520
United States
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, 21201
United States
Dana Farber Cancer Institute
Boston, Massachusetts, 02215
United States
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
United States

Collaborators and Investigators

Sponsor: Miltenyi Biomedicine GmbH

  • Remi Kaleta, MD, STUDY_DIRECTOR, Miltenyi Biomedicine GmbH

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-15
Study Completion Date2039-12-01

Study Record Updates

Study Start Date2024-05-15
Study Completion Date2039-12-01

Terms related to this study

Keywords Provided by Researchers

  • Chimeric antigen receptor
  • CAR T
  • CD19
  • CD20

Additional Relevant MeSH Terms

  • Non Hodgkin Lymphoma